

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

Answers should not exceed 60 words per question

- **Investment Rational**

BiomX is a clinical stage microbiome product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as cystic fibrosis, atopic dermatitis and inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer.

- **Business Strategy**

Our goal is to develop multiple products based on the ability of phage to precisely target components of the microbiome and on our ability to screen, identify and combine different phage, both naturally occurring and created using synthetic engineering, to develop phage-based therapies intended to address both large-market and orphan diseases.

Core Technology

We develop phage cocktails that target and kill specific pathogenic bacteria. Our phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development of bacterial resistance, among other characteristics.

- **Product Profile/Pipeline**

We decided to focus on our cystic fibrosis and atopic dermatitis programs in 2022, both expected to produce proof-of-concept data in 2022. We have additional programs in inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer.

- **What's Next?**